- AI agents provider Parloa raises $350mn Series D round
Parloa has raised USD 350mn for its Series D round led by General Catalyst with EQT Ventures, Altimeter Capital, Durable Capital Partners and Mosaic Ventures also participating. This round of funding, coming seven months after its Series C, to facilitate global expansion in the U.S. and Europe, enhance its AI Agent Management Platform and launch the Parloa Promise, a commitment to human-centric responsible AI.
The recent round values the company at USD 3bn. - Olelo Intelligence completes $1mn angel round
AI sales coaching platform, Olelo, has completed a USD 1mn angel round to deepen its product range and continue to grow in the U.S.’ USD 190bn auto repair sector. The round was led by Hawai’i Angels, which contributed USD 500,000. Olelo Intelligence is a Hawaii-based AI sales guidance platform for high-volume automotive repair shops. It helps operators increase revenue by identifying sales opportunities in service advisor calls and providing actionable insights. - Flybridge Capital Partners leads VoiceRun’s $5.5mn seed round
Flybridge Capital Partners has led VoiceRun’s USD 5.5mn seed round alongside RRE Ventures and Link Ventures. The full-stack enterprise platform will use the funding to expand its Voice AI solutions and go-to-market strategy. The funding comes at a time when enterprises are moving beyond demos and pilots and are deploying agents that meet reliability, security and governance expectations. - PulseAI closes seed funding round
PulseAI has closed its seed round of funding led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The AI-enabled cardiac diagnostics company will use the funding to speed-up the deployment of its AI-ECG technology and advance its pathway through US FDA 510(k) clearance. Despite the importance of ECGs as a frontline diagnostic tool, its interpretation remains highly dependent on specialist training and manual analysis. This often leads to delays, diagnostic variability, and missed opportunities for early intervention. PulseAI’s AI-ECG platform is designed to address this challenge directly by delivering high-performance clinical decision support in both primary and acute care settings. - Neuramint to build agent workflow platform with $5mn seed investment
Web 3 AI company Neuramint has raised a USD 5mn seed funding round from Web3 and AI-focused investment firms Maelstrom, Borderless Capital, Selini Capital, Symbolic Capital, Lattice Fund and Node Capital. The company enables developers to build and manage autonomous Web3 workflows and the funding will accelerate platform development, expand Web3-native SDK integrations and support the forthcoming launch of Neuramint Beta. It will also drive further integration with major DeFi protocols and blockchain networks. - Converge Bio announces $25mn Series A round
Converge Bio, an AI platform that enables biotech and pharmaceutical companies to accelerate drug discovery and development, has raised a USD 25mn Series A round of funding. Despite momentum in the AI drug discovery sector, it is still insufficient to meet the rigor of drug development, lacking high-quality data, the right architecture for the domain and a tight experimental validation loop. According to Converge Bio, its platform combines multiple proprietary models into an end-to-end system that plugs directly into existing drug development workflows. The round was led by Bessemer Venture Partners with TLV Partners, Vintage Investment Partners, Saras Capital and angel investors. - WitnessAI secures $58mn strategic funding
WitnessAI has secured strategic funding for product expansion and to accelerate its global go-to-market strategy. The investment round was led by Sound Ventures, with participation from Fin Capital, Qualcomm Ventures, Samsung Ventures and Forgepoint Capital Partners. The company has also unveiled its expanded agentic AI governance capabilities that bring observability to global enterprises developing and deploying AI agents.